Purpose:
To determine optimal values for parameters of manual normal tissue objectives (mNTO) in non-coplanar RapidArc (RA) SRS plans and compare them with HyperArc (HA) plans
Methods and Materials:
Eighteen patients with single solitary brain metastases, receiving 21 Gy prescriptions, were retrospectively enrolled. Non-coplanar RapidArc plans (RA-mNTO) were generated using mNTO for a range of dose fall-off values (0.1–5.0 mm− 1) and end dose values (50%, 25%, 10%). Additionally, HyperArc plans were generated using SRS NTO (HA-sNTO) and manual NTO (HA-mNTO), with optimal parameters derived from RA-mNTO plans. Plans were created using TrueBeam 6 MV-FFF and Eclipse 16.1 TPS. Plans were evaluated using parameters: Paddick Conformity Index (CI), Gradient Index (GI), Homogeneity Index (HI), Brain-GTV (18Gy, 15Gy & 12Gy), MU, and delivery accuracy. Plan comparisons utilized an integrated scoring approach and Wilcoxon signed-rank test.
Results:
The optimal RA-mNTO plan, with 0.5 mm− 1 dose fall-off and 25% end-dose values, significantly surpassed HA plans (p < 0.05) in CI, GI, and HI values (0.92 ± 0.02, 2.99 ± 0.15, 0.32 ± 0.05 vs. 0.91 ± 0.03, 3.40 ± 0.18, 0.39 ± 0.04 for HA-sNTO, and 0.91 ± 0.03, 3.16 ± 0.23, 0.40 ± 0.05 for HA-mNTO). Furthermore, RA-mNTO significantly (p < 0.05) reduced brain doses at V18Gy (0.90 ± 0.40), V15Gy (1.85 ± 0.77), and V12Gy (3.27 ± 1.35) compared to HA-sNTO (1.16 ± 0.51, 2.37 ± 1.01, 4.07 ± 1.72) and HA-mNTO (1.05 ± 0.44, 2.12 ± 0.86, 3.62 ± 1.45). Moreover, RA-mNTO showed significantly (p < 0.05) lower MUs (8302 ± 934) compared to HA (9556 ± 1005) and HA-mNTO (9327 ± 390), and higher gamma pass rates (99.8 ± 0.35) than HA-sNTO (98.9 ± 0.61) and HA-mNTO (99.1 ± 0.47).
Conclusion:
Non-coplanar RA plans with optimal mNTO settings outperformed both HA-sNTO and HA-mNTO plans for all studied dosimetric parameters.